

## SHEA Spring 2024 Abstracts

### Presentation Type:

Poster Presentation - Top Oral Abstract

**Subject Category:** Antibiotic Stewardship

### Identifying Outpatient-Specialized High-Volume Prescribers of Antibiotics in Older Adult Populations – Philadelphia, PA 2021

Giovanny Zapata, Philadelphia Department of Public Health; Jenna Scully, Philadelphia Department of Public Health; Tiina Peritz, Philadelphia Department of Public Health and Jane Gould, Philadelphia Department of Public Health

**Background:** Inappropriate antibiotic use promotes antibiotic resistance which poses a threat to public health. Outpatient settings are responsible for 80-90% of all antibiotic use, yet up to 50% of these prescriptions may be inappropriate and at least 33% completely unnecessary. To promote outpatient antibiotic stewardship (AS), the Philadelphia Department of Public Health (PDPH) identified outpatient high-volume prescribers (HVPs) in Philadelphia and provided them with peer comparison letters along with evidence-based AS educational resources. **Method:** We identified HVPs using overall and drug specific antibiotic volume and rates from the Centers of Medicare and Medicaid Services (CMS) Part D Prescribers by Provider and by Provider and Drug publicly available datasets for 2021. We restricted analyses to Philadelphia prescribers specializing in internal medicine, family practice, or general practice with antibiotic and beneficiary claim counts  $\geq 11$ . We further restricted the Provider and Drug dataset to prescribers of high-consequence drugs: levofloxacin, ciprofloxacin, and azithromycin. Prescribers with subspecialties where these three drugs are commonly used appropriately were excluded from letter distribution. We analyzed U.S. Census Bureau American Community Survey (ACS) data for overall HVPs on census tract-level to describe health equity demographic characteristics. **Result:** A total of 1,001 prescribers with 67,145 total antibiotic claims, and 306 unique prescribers (77 levofloxacin, 176 ciprofloxacin, and 250 azithromycin) with 37,057 total antibiotic claims met the inclusion criteria in the Provider and the Provider and Drug datasets, respectively. There were 101 overall HVPs, and 89 unique drug-specific HVPs (20 levofloxacin, 45 ciprofloxacin, and 63 azithromycin) based on the highest 10% and 25% of prescribers by antibiotic volume, respectively. The overall HVPs contributed 42.0% of all antibiotic claims. The drug-specific HVPs contributed 60.5% of all antibiotic claims and 55.5% of levofloxacin, ciprofloxacin, and azithromycin claims. These 3 drugs contributed 45.1% of all antibiotic claims. Among the overall and drug-specific HVPs, we sent peer comparison letters to the top 10 by rate per 1,000 beneficiaries (overall) and per 1,000 antibiotic claims (drug-specific), who fell within the following prescribing rates: overall 954-2,714, levofloxacin 84-396, ciprofloxacin 288-723, and azithromycin 496-1,000. **Conclusion:** This initiative identified prescribers at risk for inappropriate use of antibiotics, and empowered these same prescribers to self-reflect on how they prescribe antibiotics. Efforts by local health departments to provide HVPs with peer comparison feedback and AS educational resources may improve the provider knowledge and prescribing habits across different healthcare systems, targeting prescribers at highest risk for misuse or overuse of antibiotics.

**Disclosure:** Jane Gould: Spouse receives salary support- Incyte

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s1

doi:10.1017/ash.2024.96

### Presentation Type:

Poster Presentation - Top Oral Abstract


**Subject Category:** COVID-19

### Association between hospital-onset SARS-CoV-2 and ending universal admission testing and masking at five US hospitals

Theodore Pak, Massachusetts General Hospital; Sanjat Kanjilal, Harvard Medical School / Harvard Pilgrim Healthcare Institute; Cara McKenna, Harvard Pilgrim Healthcare Institute; Chanu Rhee, Brigham and Women's Hospital / Harvard Medical School and Michael Klompas, Harvard Medical School

**Background:** Many US hospitals have stopped universal masking and testing all patients on admission for SARS-CoV-2. We assessed the association of hospital-onset SARS-CoV-2 infections in five Massachusetts hospitals. **Method:** We conducted a retrospective study of all patients admitted between March 6, 2020 and December 14, 2023 and identified hospital-onset SARS-CoV-2 infections (newly positive SARS-CoV-2 PCR tests  $>4d$  after arrival) and community-onset infections (newly positive  $\leq 4d$  after arrival). We excluded cases if local infection control teams discontinued precautions within 4d (suggesting a false positive or remote/resolved infection). We calculated weekly ratios between hospital-onset and community-onset SARS-CoV-2 cases to account for changes in community SARS-CoV-2 incidence over time. We then performed interrupted time series analysis, looking for changes in the ratio of hospital-onset to community-onset cases across three periods: pre-Omicron period with universal testing and masking in place (March 6, 2020–Dec 16, 2021); Omicron period with universal testing and masking in place (Dec 17, 2021–May 11, 2023); and Omicron period without universal testing and masking (May 12, 2023–Dec 14, 2023). We performed medical record reviews on 100 randomly selected hospital-onset cases after May 12, 2023 to examine if community-onset cases were being misclassified as hospital-onset cases. **Result:** During the study period, there were 626,908

**Figure. Ratio of new hospital-onset SARS-CoV-2 infections to admissions for community-onset SARS-CoV-2 infection at five Massachusetts hospitals.**



Mean weekly ratios of new hospital-onset SARS-CoV-2 infections versus new community-onset SARS-CoV-2 admissions. Hospital-onset infections were defined as a diagnosis  $>4d$  after arrival, and community-onset infections diagnosed  $\leq 4d$  from arrival. The dashed vertical line denotes when Omicron became the dominant variant in Massachusetts ( $>50\%$  of sequenced samples). The solid vertical line demarcates when universal admission testing and masking ended. Horizontal lines indicate the mean values for each period, and the shaded areas represent a 95% confidence interval.